A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
about
Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic reviewAre VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials.The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysisAn exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre.Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South KoreaRisk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review.Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trialsRisk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.Nintedanib in non-small cell lung cancer: from preclinical to approval.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations.Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.Strategies targeting angiogenesis in advanced non-small cell lung cancer.Effects of local irradiation combined with sunitinib on early remodeling, mitochondria, and oxidative stress in the rat heartAdverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis.Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trialsMeta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer.Newly developed anti-angiogenic therapy in non-small cell lung cancer.Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.Antiangiogenic therapies in non-small-cell lung cancer.[Progress of platelet derived grow factor family in non-small cell lung cancer].
P2860
Q27022535-49BC3B57-2C49-4306-9D7A-AF0FCEBA0329Q28085104-759E84BE-6E3F-4B8B-99C9-C72FA1532781Q33418555-FBFA804E-0687-44E5-9E9E-29B075BB375DQ34352627-A1495005-49D4-4F3C-BCDC-39768108D995Q35649624-928585E9-5340-4936-BEB9-CEA1B679EA3DQ35714621-8F0786E5-A2B2-400B-8107-929DC557CA0BQ36092393-D716BC68-9C55-4038-9700-52DE719E3D70Q37042424-CEC7A30F-A42E-4630-B43B-8E013C47A415Q37624187-91B6C6DB-1260-47F6-9934-B7BBF858482BQ37670497-F6925568-0430-498C-A03E-D95604CBB302Q37701719-36F81425-F8BD-4C9E-A6A8-A233A4CF425BQ38284400-7E5EBA34-DAEC-4039-B0FC-386FAD517085Q38412048-2ACB09B1-D90D-4129-9F1C-DAA919CB5C47Q38525073-5A25A360-E481-455F-8EB3-45491B8CDE10Q38936376-1924BE19-9E54-4821-88AB-AD1AAB12A771Q38964908-24585071-AAC3-4C28-A118-B0A183C5142AQ39538184-43691483-A32C-4F23-8932-D8BA3B5D84A9Q41593429-8DECB069-B641-4C66-913A-AB27A7494307Q41902920-9FB0932A-F09A-4923-97FB-D8F69244705FQ42359608-511315C6-9F2F-4ABD-A2D9-D15B6B26527DQ42700668-D3482E74-F4B6-4C7A-91F2-76A2CD02BD63Q44669628-69413018-5181-435E-88FD-9925E02C7AB8Q52668159-236D3D6F-B5E6-4E58-9EA7-8A5C8D1673F8Q55069554-1A8CAFB1-5135-4F44-8BCD-DF82A09458C8Q55168137-C76B1D18-5D21-4417-84A5-ACE483ACAEAEQ55464615-EB0BAC16-93D5-4EAE-9DA3-1FCEACE4E21E
P2860
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A randomized, double-blind, ph ...... mall-cell lung cancer (NSCLC).
@ast
A randomized, double-blind, ph ...... mall-cell lung cancer (NSCLC).
@en
type
label
A randomized, double-blind, ph ...... mall-cell lung cancer (NSCLC).
@ast
A randomized, double-blind, ph ...... mall-cell lung cancer (NSCLC).
@en
prefLabel
A randomized, double-blind, ph ...... mall-cell lung cancer (NSCLC).
@ast
A randomized, double-blind, ph ...... mall-cell lung cancer (NSCLC).
@en
P2093
P356
P1433
P1476
A randomized, double-blind, ph ...... small-cell lung cancer (NSCLC)
@en
P2093
C Gridelli
E Chmielowska
G R Blumenschein
H J M Groen
J A Williams
P304
P356
10.1093/ANNONC/MDT212
P577
2013-06-20T00:00:00Z